Trials / Completed
CompletedNCT03463681
A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
A Phase 2 Open Label Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma Pretreated With One immunochecKPOint INhibiTor (Anti PD1/PDL1): the BREAKPOINT Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label single arm, multicenter, phase II study designet To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabometyx | cabozantinib 60 mg orally once daily |
Timeline
- Start date
- 2018-06-11
- Primary completion
- 2021-04-08
- Completion
- 2021-04-08
- First posted
- 2018-03-13
- Last updated
- 2021-04-26
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03463681. Inclusion in this directory is not an endorsement.